Author(s): Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al.
Objective: To determine the relation between exposure to glycaemia over time and the risk of macrovascular or microvascular complications in patients with type 2 diabetes.
Design: Prospective observational study.
Setting: 23 hospital based clinics in England, Scotland, and Northern Ireland.
Participants: 4585 white, Asian Indian, and Afro-Caribbean UKPDS patients, whether randomised or not to treatment, were included in analyses of incidence; of these, 3642 were included in analyses of relative risk.
Outcome measures: Primary predefined aggregate clinical outcomes: any end point or deaths related to diabetes and all cause mortality. Secondary aggregate outcomes: myocardial infarction, stroke, amputation (including death from peripheral vascular disease), and microvascular disease (predominantly retinal photo-coagulation). Single end points: non-fatal heart failure and cataract extraction. Risk reduction associated with a 1% reduction in updated mean HbA(1c) adjusted for possible confounders at diagnosis of diabetes.
Results: The incidence of clinical complications was significantly associated with glycaemia. Each 1% reduction in updated mean HbA(1c) was associated with reductions in risk of 21% for any end point related to diabetes (95% confidence interval 17% to 24%, P<0.0001), 21% for deaths related to diabetes (15% to 27%, P<0.0001), 14% for myocardial infarction (8% to 21%, P<0.0001), and 37% for microvascular complications (33% to 41%, P<0.0001). No threshold of risk was observed for any end point.
Conclusions: In patients with type 2 diabetes the risk of diabetic complications was strongly associated with previous hyperglycaemia. Any reduction in HbA(1c) is likely to reduce the risk of complications, with the lowest risk being in those with HbA(1c) values in the normal range (<6.0%).
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/10938048
Author(s): Selby JV, Ray GT, Zhang D, Colby CJ
Author(s): Sidorov J, Shull R, Tomcavage J, Girolami S, Lawton N, et al.
Author(s): Cutajar J
Author(s): Costa J, Borges M, David C, Vaz Carneiro A
Author(s): IDF Clinical Guidelines Task Force
Author(s): Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.
Author(s): Selby JV, Karter AJ, Ackerson LM, Ferrara A, Liu J
Author(s): The Mount Hood 4 Modeling Group
Author(s): Clark CM Jr, Snyder JW, Meek RL, Stutz LM, Parkin CG
Author(s): Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, et al.
Author(s): Carr MC, Brunzell JD
Author(s): van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, et al.
Author(s): Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group
Author(s): Serrano Rios M
Author(s): Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al.
Author(s): Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR
Author(s): Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, et al.
Author(s): Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et al.
Author(s): Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R
Author(s): Park JY, Kim HK, Chung YE, Kim SW, Hong SK, et al.
Author(s): Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al.
Author(s): Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, et al.
Author(s): Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, et al.
Author(s): Anderson JW, Kendall CW, Jenkins DJ
Author(s): Metascreen Writing Committee, Bonadonna R, Cucinotta D, Fedele D, Riccardi G, et al.
Author(s): Costa LA, Canani LH, Lisbôa HR, Tres GS, Gross GL
Author(s): Handelsman Y, Jellinger PS
Author(s): Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, et al.